Canada’s life sciences sector has been at the forefront of our country’s response to the COVID-19 pandemic. Our sector also has significant potential to drive Canada’s economic recovery and build up our resilience to future health challenges.
In this context, life sciences sector stakeholders remain deeply concerned about the federal government’s patented medicine price controls and the Patented Medicine Price Review Board’s proposal to halve the transition period for companies.
The rush to implement the new pricing system will exacerbate challenges in bringing vaccines and medicines to Canadians and divert companies’ attention and resources away from responding to the crisis at the worst time possible.
Read Life Sciences Ontario and BioQuebec’s to the PMPRB 2021 Guidelines consultation to learn more.
